e-learning
resources
Vienna 2003
Sunday 28.09.2003
Pharmacological treatment strategies in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs
C. G. Löfdahl, E. Andreasson, K. Svensson, A. Ericsson (Lund, Sweden)
Source:
Annual Congress 2003 - Pharmacological treatment strategies in COPD
Session:
Pharmacological treatment strategies in COPD
Session type:
Thematic Poster Session
Number:
433
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. G. Löfdahl, E. Andreasson, K. Svensson, A. Ericsson (Lund, Sweden). Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs. Eur Respir J 2003; 22: Suppl. 45, 433
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 250s
Year: 2002
Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Tiotropium reduces health resource utilization associated with COPD exacerbations
Source: Eur Respir J 2004; 24: Suppl. 48, 513s
Year: 2004
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Budesonide/formoterol improves the wellbeing of patients with COPD: results from a real-life setting
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005
Nurse-assisted medical management of COPD patients at home is cost effective and improves patients‘ satisfaction considerably
Source: Eur Respir J 2007; 30: Suppl. 51, 191s
Year: 2007
How can we improve patient use of inhaler devices in COPD?
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
Salmeterol 50mcg bid significantly improves health status in COPD patients
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The economic impact recurrent inhaler versus single instructions in asthma and COPD patients
Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence
Year: 2021
Comparison of total cost of health services among asthmatic and COPD patients in uni-speciality hospital with general hospital
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
Suboptimal asthma control in patients receiving long-term maintenance therapy
Source: Annual Congress 2006 - The challenges of managing asthma in primary care
Year: 2006
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Improving asthma care with use of asthma action plan and inhaler technique check in a children‘s hospital
Source: Annual Congress 2010 - Quality of life, asthma control and monitoring childhood asthma
Year: 2010
Reduced cost of unscheduled healthcare resource use in patients with well controlled asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 44s
Year: 2005
The importance of inhaler technique education in asthma and COPD: a long-term follow-up
Source: International Congress 2019 – Medical education
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept